Systematic review of the effect of dopamine receptor agonists on patient health-related quality of life

Parkinsonism and Related Disorders

Volumn 15, Issue SUPPL. 4, 2009, Pages

  Martinez Martin, Pablo ^a   Kurtis, Mónica M ^b  

^a CARLOS III INSTITUTE OF HEALTH   (Spain)

^b Unidad Radiocirugia   (Spain)

Author keywords

Dopamine receptor agonists; Health related quality of life; Magnitude of change; Parkinson's disease; Systematic review

Indexed keywords

APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; CATECHOL METHYLTRANSFERASE INHIBITOR; DIHYDROERGOCRYPTINE; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; LISURIDE; PERGOLIDE; PLACEBO; PRAMIPEXOLE; ROPINIROLE; ROTIGOTINE; SERTRALINE; TOLCAPONE; ANTIPARKINSON AGENT;

ADD ON THERAPY; ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DEPRESSION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; MOTOR DYSFUNCTION; PARKINSON DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; CLINICAL TRIAL (TOPIC); HEALTH STATUS; PATHOLOGY; PROCEDURES; PSYCHOLOGY;

ANTIPARKINSON AGENTS; CLINICAL TRIALS AS TOPIC; DOPAMINE AGONISTS; HEALTH STATUS; HUMANS; PARKINSON DISEASE; QUALITY OF LIFE;

EID: 72749114107     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(09)70837-5     Document Type: Article

References (33)

1. Hornykiewicz O. Chemical neuroanatomy of the basal ganglia - normal and in Parkinson's disease. J Chem Neuroanat 22 (2001) 3-12
2. Barbeau A. The pathogenesis of Parkinson's disease: a new hypothesis. Can Med Assoc J 87 (1962) 802-807
3. Cotzias G.C., Van Woert M.H., and Schiffer L.M. Aromatic amino acids and modification of parkinsonism. N Engl J Med 276 (1967) 374-379
4. Calne D.B., Teychenne P.F., Leigh P.N., Bamji A.N., and Greenacre J.K. Treatment of parkinsonism with bromocriptine. Lancet 2 (1974) 1355-1356
5. Miyasaki J.M., Martin W., Suchowersky O., Weiner W.J., and Lang A.E. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 58 (2002) 11-17
6. Quinn N. Drug treatment of Parkinson's disease. BMJ 310 (1995) 575-579
7. Chase T.N., Engber T.M., and Mouradian M.M. Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson's disease. Neurology 44 Suppl 6 (1994) 15-18
8. Rascol O., Brooks D.J., Korczyn A.D., De Deyn P.P., Clarke C.E., and Lang A.E. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole of levodopa. 056 Study Group. N Engl J Med 342 (2000) 1484-1491
9. Martinez-Martin P. An introduction to the concept of "quality of life in Parkinson's disease". J Neurol 245 Suppl 1 (1998) 2-6
10. Holloway R.G., Shoulson I., Fahn S., Kieburtz K., Lang A., Marek K., et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 61 (2004) 1044-1053
11. Noyes K., Dick A.W., Holloway R.G., and Parkinson Study Group. Pramipexole versus levodopa in patients with early Parkinson's disease: effect on generic and disease-specific quality of life. Value Health 9 (2006) 28-38
12. Martinez-Martin P., and Deuschl G. Effect of medical and surgical interventions on health-related quality of life in Parkinson's disease. Mov Disord 22 (2007) 757-765
13. Task Force of the Movement Disorder Society. Management of Parkinson's disease: an evidence-based review. Mov Disord 17 Suppl 4 (2002) S1-S6
14. Kazis L.E., Anderson J.J., and Meenan R.F. Effect sizes for interpreting changes in health status. Med Care 27 Suppl 3 (1989) S178-S189
15. Wyrwich K.W., and Wolinsky F.D. Identifying meaningful intra-individual change standards for health-related quality of life measures. J Eval Clin Pract 6 (2000) 39-49
16. Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group. Neurology 49 (1997) 1060-1065
17. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. JAMA 284 (2000) 1931-1938
18. Baas H.K., and Schueler P. Efficacy of cabergoline in long-term use: results of three observational studies in 1,500 patients with Parkinson's disease. Eur Neurol 46 Suppl 1 (2001) 18-23
19. Koller W., Lees A., Doder M., Hely M., and Tolcapone/Pergolide Study Group. Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations. Mov Disord 16 (2001) 858-866
20. Barone P., Scarzella L., Marconi R., Antonini A., Morgante L., Bracco F., et al. Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study. J Neurol 253 (2006) 601-607
21. Odin P., Oehlwein C., Storch A., Polzer U., Werner G., Renner R., et al. Efficacy and safety of high-dose cabergoline in Parkinson's disease. Acta Neurol Scand 113 (2006) 18-24
22. Castaño B., Mateo D., and Giménez-Roldán S. [Shifting to subcutaneous infusion of apomorphine in advanced Parkinson's disease patients on an out-patient basis: experience and recommendations]. Neurologia 22 (2007) 133-137
23. Deuschl G., Vaitkus A., Fox G.C., Roscher T., Schremmer D., Gordin A., et al. Efficacy and tolerability of Entacapone versus Cabergoline in parkinsonian patients suffering from wearing-off. Mov Disord 22 (2007) 1550-1555
24. Fedorova N.V., and Chigir' I.P. Use of the dopamine receptor agonist Mirapex in the treatment of Parkinson's disease. Neurosci Behav Physiol 37 (2007) 539-546
25. Hauser R.A., Rascol O., Korczyn A.D., Stoessl A.J., Watts R.L., Poewe W., et al. Tenyear follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord 22 (2007) 2409-2417
26. Jankovic J., Watts R.L., Martin W., and Boroojerdi B. Transdermal rotigotine: doubleblind, placebo-controlled trial in Parkinson disease. Arch Neurol 64 (2007) 676-682
27. Pahwa R., Stacy M.A., Factor S.A., Lyons K.E., Stocchi F., Hersh B.P., et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 68 (2007) 1108-1115
28. Parkinson Study Group. Pramipexole in levodopa-treated Parkinson disease patients of African, Asian, and Hispanic heritage. Clin Neuropharmacol 30 (2007) 72-85
29. Poewe W., Rascol O., Quinn N., Tolosa E., Oertel W.H., Martignoni E., et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 6 (2007) 513-520
30. Linazasoro G., and Spanish Dopamine Agonists Study Group. Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease. Clin Neuropharmacol 31 (2008) 19-24
31. Nyholm D., Constantinescu R., Holmberg B., Dizdar N., and Askmark H. Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations. Acta Neurol Scand 119 (2009) 345-348
32. Clarke C.E., and Guttman M. Dopamine agonist monotherapy in Parkinson's disease. Lancet 360 (2002) 1767-1769
33. Gallagher D.A., and Schrag A. Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease. CNS Drugs 22 (2008) 563-586